These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 16144944)

  • 61. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Archer GE; Wikstrand CJ; Bigner DD; Zalutsky MR
    Cancer Res; 1997 Apr; 57(8):1510-5. PubMed ID: 9108453
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
    Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1067-75. PubMed ID: 9620065
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
    Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
    Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
    Bigner SH; Humphrey PA; Wong AJ; Vogelstein B; Mark J; Friedman HS; Bigner DD
    Cancer Res; 1990 Dec; 50(24):8017-22. PubMed ID: 2253244
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
    Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27.
    Schrappe M; Bumol TF; Apelgren LD; Briggs SL; Koppel GA; Markowitz DD; Mueller BM; Reisfeld RA
    Cancer Res; 1992 Jul; 52(14):3838-44. PubMed ID: 1617657
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
    Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
    Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
    Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
    Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.
    Humphrey PA; Wong AJ; Vogelstein B; Friedman HS; Werner MH; Bigner DD; Bigner SH
    Cancer Res; 1988 Apr; 48(8):2231-8. PubMed ID: 3258189
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
    Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
    Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts.
    Deberne M; Levy A; Mondini M; Dessen P; Vivet S; Supiramaniam A; Vozenin MC; Deutsch E
    Anticancer Drugs; 2013 Jul; 24(6):599-608. PubMed ID: 23698251
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
    J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.